Detection of Serum Δ9-Tetrahydrocannabinol and Cannabidiol After a Single Oral Dose of Maziren Pills in Patients with Functional Constipation: A Prospective Observational Pilot Study

Abstract

Objectives: Cannabis seed is used for functional constipation, but residual seed coat may contain Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). This study evaluated serum cannabinoid exposure and safety after Maziren pill administration.Methods: This prospective pilot study enrolled 20 adults aged 19-65 years with Rome IV functional constipation. Participants received one standardized 3.2-g sachet of Maziren pills containing 840 mg cannabis seed. Serum THC and CBD were measured by ultra-performance liquid chromatography-mass spectrometry before dosing and at 1, 2, and 3 hours. Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, and creatinine were assessed before dosing and 3 hours after dosing.Results: THC and CBD remained below detection limits at all time points. No clinically meaningful changes in liver or kidney function occurred; only blood urea nitrogen decreased significantly (p=0.02).Conclusion: A single dose resulted in no detectable serum THC or CBD within 3 hours, providing preliminary short-term safety data.